Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

CLAG-Based Induction Therapy in Previously Untreated High Risk AML Patients

Karen Seiter, MD, Stephanie Germani, FNP, Julie Martin, FNP, Rosemarie Raffa, FNP, Michele Reilly, ANP, Nasir Ahmed, MD, Paul Baskind, Delong Liu, MD PhD

Blood (2015) 126 (23): 4892.

https://doi.org/10.1182/blood.V126.23.4892.4892

Published: 2015

Journal Articles

High Response Rate and Prolonged Survival in Patients with Primary Refractory Acute Myelogenous Leukemia Treated with Decitabine Salvage Therapy

Ana Fernandez, MD, Dhaval Shah, MD, MBBS, Delong Liu, MD, PhD, Nasir Ahmed, MD, Elizabeth Lulaj, MD, Karen Seiter, MD

Blood (2011) 118 (21): 4280.

https://doi.org/10.1182/blood.V118.21.4280.4280

Published: 2011

Journal Articles

Rasburicase Effectively Lowers Serum Uric Acid Levels in High Risk, Poor Performance Status Patients with Hematologic Malignancies

Doris Ponce, MD, Delong Liu, MD, PhD, Muhammad Rasul, MD, Nasir Ahmed, MD, Marie Dimicco, PhD, Karen Seiter, MD

Blood (2008) 112 (11): 4012.

https://doi.org/10.1182/blood.V112.11.4012.4012

Published: 2008

Journal Articles

Feasibility Study of Temozolomide Maintenance Therapy in Elderly Patients with AML Following Induction Therapy with High Dose Mitoxantrone and High Dose Ara-C.

Doris Ponce, MD, Sreedhar Katragadda, MD, Delong Liu, MD.PhD, Muhammad Rasul, MD, Nasir Ahmed, MD, Tauseef Ahmed, MD, Karen Seiter, MD

Blood (2007) 110 (11): 4383.

https://doi.org/10.1182/blood.V110.11.4383.4383

Published: 2007

Journal Articles

Phase I Study of Temozolomide and Cisplatin in Patients with Acute Leukemia.

Sreedhar Katragadda, MD, Delong Liu, MD PhD, Dorota Halicka, PhD, Sanford Kempin, MD, Nasir Ahmed, MD, Tauseef Ahmed, MD, Karen Seiter, MD

Blood (2006) 108 (11): 4542.

https://doi.org/10.1182/blood.V108.11.4542.4542

Published: 2006

Journal Articles

Feasibility Study of Temozolomide Maintenance Therapy in Elderly Patients with AML Following Induction Therapy with High Dose Mitoxantrone and High Dose Ara-C.

Sreedhar Katragadda, MD, Muhammad Arshad, MD, Delong Liu, MD PhD, Nasir Ahmed, MD, Quihu Shi, PhD, Tauseef Ahmed, MD, Karen Seiter, MD

Blood (2006) 108 (11): 4546.

https://doi.org/10.1182/blood.V108.11.4546.4546

Published: 2006

NARROW

CLAG-Based Induction Therapy in Previously Untreated High Risk AML Patients

High Response Rate and Prolonged Survival in Patients with Primary Refractory Acute Myelogenous Leukemia Treated with Decitabine Salvage Therapy

Rasburicase Effectively Lowers Serum Uric Acid Levels in High Risk, Poor Performance Status Patients with Hematologic Malignancies

Feasibility Study of Temozolomide Maintenance Therapy in Elderly Patients with AML Following Induction Therapy with High Dose Mitoxantrone and High Dose Ara-C.

Phase I Study of Temozolomide and Cisplatin in Patients with Acute Leukemia.

Feasibility Study of Temozolomide Maintenance Therapy in Elderly Patients with AML Following Induction Therapy with High Dose Mitoxantrone and High Dose Ara-C.

Email alerts

ASH Publications

American Society of Hematology

CLAG-Based Induction Therapy in Previously Untreated High Risk AML Patients

High Response Rate and Prolonged Survival in Patients with Primary Refractory Acute Myelogenous Leukemia Treated with Decitabine Salvage Therapy

Rasburicase Effectively Lowers Serum Uric Acid Levels in High Risk, Poor Performance Status Patients with Hematologic Malignancies

Feasibility Study of Temozolomide Maintenance Therapy in Elderly Patients with AML Following Induction Therapy with High Dose Mitoxantrone and High Dose Ara-C.

Phase I Study of Temozolomide and Cisplatin in Patients with Acute Leukemia.

Feasibility Study of Temozolomide Maintenance Therapy in Elderly Patients with AML Following Induction Therapy with High Dose Mitoxantrone and High Dose Ara-C.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only